Get the Stockscreener App
17.51
4.05%
-0.74
After Hours:
16.84
-0.67
-3.83%
Tectonic Therapeutic Inc stock is traded at $17.51, with a volume of 598.78K.
It is down -4.05% in the last 24 hours and up +14.90% over the past month.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
See More
Previous Close:
$18.25
Open:
$18.12
24h Volume:
598.78K
Relative Volume:
1.18
Market Cap:
$327.65M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.96%
1M Performance:
+14.90%
6M Performance:
-19.48%
1Y Performance:
-57.17%
1-Day Range:
$16.59
$18.51
1-Week Range:
$16.59
$26.00
52-Week Range:
$13.70
$61.07
Tectonic Therapeutic Inc Stock (TECX) Company Profile
Name
Tectonic Therapeutic Inc
Sector
Industry
Phone
(339) 666-3320
Address
490 ARSENAL WAY, WATERTOWN
Compare TECX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TECX
Tectonic Therapeutic Inc
|
17.51 | 341.50M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tectonic Therapeutic Inc Stock (TECX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Apr-21-25 | Initiated | Mizuho | Outperform |
| Nov-20-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Jun-26-24 | Initiated | Piper Sandler | Overweight |
| Jun-24-24 | Initiated | TD Cowen | Buy |
| Dec-18-23 | Downgrade | Mizuho | Buy → Neutral |
| Jan-05-22 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Mar-31-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Apr-05-19 | Initiated | Janney | Buy |
| Oct-10-18 | Initiated | Guggenheim | Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-17-18 | Initiated | H.C. Wainwright | Buy |
| Jul-16-18 | Initiated | Wedbush | Outperform |
| Jul-16-18 | Initiated | Wells Fargo | Outperform |
View All
Tectonic Therapeutic Inc Stock (TECX) Latest News
It is Poised to be a Bull Market for Tectonic Therapeutic Inc (TECX) - setenews.com
How high can Tectonic Therapeutic Inc. stock go2025 Biggest Moves & Short-Term Trading Alerts - newser.com
Chart based analysis of Tectonic Therapeutic Inc. trendsJuly 2025 Patterns & Community Consensus Trade Alerts - newser.com
Tectonic Therapeutic Inc expected to post a loss of $1.05 a shareEarnings Preview - TradingView
Is Tectonic Therapeutic Inc. meeting your algorithmic filter criteriaMarket Risk Report & Weekly High Return Stock Opportunities - newser.com
How to track smart money flows in Tectonic Therapeutic Inc.Earnings Miss & Expert Verified Movement Alerts - newser.com
Can Tectonic Therapeutic Inc. stock sustain market leadershipWeekly Stock Recap & Weekly Setup with ROI Potential - newser.com
What data driven models say about Tectonic Therapeutic Inc.’s futureJuly 2025 Short Interest & Verified High Yield Trade Plans - newser.com
Price action breakdown for Tectonic Therapeutic Inc.Share Buyback & Verified Momentum Stock Watchlist - newser.com
Is Tectonic Therapeutic Inc. stock attractive for retirement portfoliosJuly 2025 Momentum & Safe Capital Growth Trade Ideas - newser.com
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Is Tectonic Therapeutic Inc. forming a reversal patternQuarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Tectonic Therapeutic (TECX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
What recovery options are there for Tectonic Therapeutic Inc.July 2025 Setups & Entry and Exit Point Strategies - newser.com
What institutional flow reveals about Tectonic Therapeutic Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com
Transcript : Tectonic Therapeutic, Inc.Special Call - MarketScreener
Can Tectonic Therapeutic Inc. stock deliver consistent earnings growth2025 Top Gainers & Community Verified Swing Trade Signals - newser.com
Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer By Investing.com - Investing.com Nigeria
Tectonic Therapeutic Reports Positive Phase 1b Trial Results - TipRanks
Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer - Investing.com
Tectonic Therapeutic, Inc. Announces Positive Results from TX45 Phase 1b Part B Trial - TradingView
Why Tectonic Therapeutic Stock Soared 30% After-Hours Today - Asianet Newsable
Tectonic surges on phase 1b data for pulmonary hypertension asset - Seeking Alpha
Tectonic Therapeutic stock soars after positive Phase 1b data for heart failure drug - Investing.com Canada
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - The Manila Times
Tectonic (NASDAQ: TECX) reports -29.2% PCWP, +17.3% CO with TX45 in PH‑HFrEF Phase 1b - Stock Titan
Tectonic Therapeutic Inc Stock (TECX) Financials Data
There is no financial data for Tectonic Therapeutic Inc (TECX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):